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ing (PONV) continues to be a concern that needs to be addressed. There was a persistently high
incidence of PONV despite prophylaxis with, metoclopramide, droperidol, dimenhydrinate or
ondansetron when each was used alone in ‘at risk’ patients. Dexamethasone was also used as a
stand alone drug in patients undergoing surgery. However, the current opinion questions the role
of monotherapy. Drug combinations are deemed to be more useful for balanced anti-emesis. The
aim of this study was to evaluate the prophylactic antiemetic effects of the combination dexameth-
asone–metoclopramide in patients undergoing maxillofacial procedures.
Patients and methods: In this placebo-controlled, double-blind study, 208 outpatients under stan-
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164 E.M. Manaa, S.A. Seifinduction and metoclopramide, 10 mg at the end of surgery (Group A), dexamethasone 8 mg before
anesthesia induction and placebo at the end of surgery (Group B), placebo before anesthesia induc-
tion and metoclopramide, 10 mg at the end of surgery (Group C) or placebo before anesthesia
induction and at the end of surgery (Group D). Complete response to prophylactic antiemetic med-
ication was deﬁned as no vomiting, no sustained moderate nausea and no requesting of antiemetic
drug.
Results: During predischarge period, the number of patients with complete response to prophylac-
tic antiemetic medication was signiﬁcantly higher in Groups B (90.4%) and A (86.5%) in compar-
ison with Groups D (55.8%) and C (75%). At the 24 h follow-up evaluation, complete response was
higher in Group A (96.2%) in comparison with Groups C (67.3%) and D (78.8%).
Conclusions: Dexamethasone–metoclopramide combination is not more effective than administra-
tion of dexamethasone alone in the prophylaxis of (PONV).
ª 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
The incidence of PONV has remained static over the last
20 years despite the use of short-acting anesthetics and execu-
tion of minimally invasive surgeries, most of those executed in
the ambulatory context [1].
The use of prophylactic antiemetic drugs produces greater
patient satisfaction than treatment of symptoms of PONV
[2–4]. However, it has generated a great controversy regarding
antiemetic treatment to be more cost-effective compared to
routine prophylaxis because of the introduction of newer,
more expensive antiemetic medications (antiserotoninergic
and neurokinin 1 antagonist) [5,6]. The results of multifactorial
design studies suggest that antiemetics with different mecha-
nisms of action have additive effects on the incidence of PONV
[7]. The low cost and excellent safety proﬁle of dexamethasone
have been classiﬁed as a highly cost-effective strategy in the
prevention of this adverse event [7,8]. Metoclopramide is a
medication that has been used for 40 years in the prevention
of postoperative emesis [9]. It is a very low-cost drug, and dose
of 10 mg IV, has a low incidence of adverse events [10]. Despite
its limited relevance prophylactic antiemetic (NNT [number
needed to treat] = 9.1 and 10 for early postoperative nausea
and vomiting, respectively) is the only medication approved
by the Mandatory Health Plan as an antiemetic prophylaxis
[10].
In order to determine the true beneﬁt of antiemetic prophy-
laxis with two drugs administered at different times of anesthe-
sia, we designed this clinical study comparing the efﬁcacy of
dexamethasone and metoclopramide, each of these medica-
tions used individually and with combination in preventing
PONV after outpatients’ maxillofacial surgical procedures.2. Patients and methods
After approval being obtained from the Research Committee
of the Department of Anesthesiology and the Faculty of Med-
icine, King Khalid University Hospital, King Saud University
in Riyadh, Saudi Arabia 208 patients signed written informed
consent, and scheduled electively for maxillofacial surgical
procedures (e.g. impacted tooth extraction, jaw reconstruction,
removal of cyst or tumor) were enrolled in this randomized
clinical, double-blind, placebo controlled trial. Patients be-
tween the ages of 20 and 52 years were randomly assigned toone of four treatment groups using a table of computer-gener-
ated random numbers:
(A) dexamethasone–metoclopramide group who received
dexamethasone before induction of anesthesia and metoclo-
pramide 30 min before the end of surgery, (B) dexamethasone
group, who received dexamethasone before induction of anes-
thesia and 0.9% normal saline 30 min before the end of sur-
gery, (C) metoclopramide group who received 0.9% normal
saline before anesthesia induction and metoclopramide
30 min before the end of surgery and (D) placebo group who
received 0.9% normal saline both before induction of anesthe-
sia, about 30 min before the end of surgery.
We excluded patients who had received any antiemetic
medication or who had experienced emesis or nausea during
a period of 24 h before surgery, pregnant, had consumed psy-
choactive substances for 24 h before surgery, who had received
steroids in a period of 6 months prior to surgery and patients
with a known allergy to the drugs studied. Also patients with
an ASA (American Society of Anesthesiology) class III or
higher. Also patients who suffer from any condition that con-
traindicated steroid administration: hypertension, heart dis-
ease, renal failure, peptic ulcer disease, diabetes, Cushing
disease, adrenal insufﬁciency, immunosuppression, recent
tuberculosis and cataracts were excluded from study. Detailed
medical history was obtained from each patient and also
demographic information including age, height, weight, ASA
physical status, prior use of drugs, previous history of PONV
or vertigo of motion.
Immediately before surgery, all patients were assessed for
nausea, anxiety, sedation, dizziness and pain using a 100 mm
verbal analog scale (VAS) (0 = none and 100 = maximum
pain). The medications were prepared to the study by the head
nurse of operating room in two numbered 5 ml syringes, which
were identical in appearance. The ﬁrst syringe (syringe labeled
#1), contained dexamethasone 8 mg, or 0.9% normal saline (in
a total volume of 5 ml) was administered 3 min before induc-
tion of anesthesia. The second syringe (syringe labeled #2),
contained metoclopramide 10 mg, or 0.9% normal saline (in
a total volume of 5 ml) was administered 30 min before the
predicted end of surgery. Patients in Group A received dexa-
methasone 8 mg in Syringe #1 and metoclopramide, 10 mg in
Syringe #2. Patients in Group B received dexamethasone
8 mg Syringe #1 and 0.9% normal saline in the Syringe #2. Pa-
tients in Group C received 0.9% normal saline in the Syringe
#1 and metoclopramide, 10 mg in Syringe #2. Patients in
Postoperative nausea and vomiting management 165Group D received 0.9% normal saline both in the Syringes #1
and #2. In the operating room, patients were monitored con-
ventionally and subsequently received a standardized anes-
thetic technique consisting of fentanyl, propofol and
rocuronium for induction and isoﬂurane for maintenance after
endotracheal intubation. At the end of surgery neuromuscular
relaxant was antagonized using neostigmine.
The anesthetic time (from start of induction to discontinu-
ation of the volatile anesthetic), the time of surgery (from the
local anesthetic inﬁltration to the placement of surgical dress-
ings), and eye opening times (from volatile anesthetic discon-
tinuation to eye opening), follow verbal commands (from the
discontinuation volatile anesthetic to lift his/her head to the
verbal command) and orientation (from the discontinuation
of the volatile anesthetic until it was able to give the name
and date of birth) were recorded. Length of stay in the post-
anesthesia care unit (PACU), and time to unassisted ambula-
tion (from the discontinuation of volatile anesthetics) which
meets hospital discharge criteria were recorded.
The standard criteria for hospital discharge included stable
vital signs, ability to ambulate without assistance, spontaneous
diuresis and absence of severe pain or nausea. One of the inves-
tigators blinded to the antiemetic treatment group recorded all
intraoperative and recovery variables, including the incidence
of PONV and the need for rescue antiemetic medication. An
episode of emesis was deﬁned as vomiting or retching or any
combination of these events occurring in rapid sequence
(<1 min between events). When the interval between episodes
of vomiting or retching was >1 min were considered separate
episodes. If the patient experienced repeated episodes (two or
more) of emesis, or moderate nausea (>40 mm on VAS) held
for 15 min or more, or if requested antiemetic, promethazine
was administered, 6.25 mg IV. If emesis or nausea persisted
for more than 15 min after administration of promethazine,
4 mg IV ondansetron was administered. The primary efﬁcacy
outcome in this study was deﬁned as a complete response to
antiemetic prophylaxis. This in turn was deﬁned as no vomit-Table 1 Patient demographic characteristics, preoperative assessme
Group A (n= 52) Group
Age (years) 32 ± 9 30 ± 1
Sex (F/M; n) 24/28 26/26
BMI (kg/m2) 24 ± 3 24 ± 3
History of smoking [n (%)] 15 (28.8) 15 (28
History of PONV [n (%)] 5 (9.6) 3 (5.8)
History of vertigo [n (%)] 4 (7.7) 3 (5.8)
Nausea VAS (0–100 mm) 11 4
Anxiety VAS (0–100 mm) 34 36
Sedation VAS (0–100 mm) 0 1
Vertigo VAS (0–100 mm) 0 0
Pain VAS (0–100 mm) 3 1
Propofol (mg) 160 ± 26 160 ±
Fentanyl (mg) 156 ± 35 156 ±
Rocuronium (mg) 30 ± 17 28 ± 1
Anesthesia time (min) 125 ± 58 121 ±
Surgery time (min) 113 ± 56 108 ±
Eye opening time (min) 17 ± 9 17 ± 1
Verbal command time (min) 20 ± 10 21 ± 1
Orientation time (min) 42 ± 20 41 ± 1
Values are mean ± SD, numbers (n), or percentages (%).
No signiﬁcant differences between groups.
F/M= female/male, BMI = body mass index, PONV= postoperative ning, no moderate nausea sustained for 15 min or more and no
application for administration of rescue antiemetic medication.
In all patients, postoperative pain was treated with mor-
phine 1.5 mg IV bolus every 10 min until the patient feels com-
fortable (<40 mm on VAS). The VAS was used to assess
nausea, anxiety, sedation, dizziness and pain immediately be-
fore the discharge. We recorded all adverse events and medica-
tions used in the PACU.
Patients were contacted within 24 h after surgery by antie-
metic blinded investigators. They were asked to report the
number of episodes of vomiting and any antiemetic medication
taken since patient left the hospital. Similarly, they were asked
to rate nausea since they were discharged using a 11-point ver-
bal scale (0 = no nausea to 10 = ‘‘worst imaginable nausea’’).
2.1. Statistical analysis
Assuming that 60% of patients undergoing maxillofacial proce-
dures under general anesthesia develop PONV and the inci-
dence of this adverse event in patients treated prophylactically
with dexamethasone is approximately 45% in previous studies,
was established by an a previous power analysis, 52 patients
were needed per group to have 80% chance to detect a 25%
reduction of PONV in Group A in relation to the Groups B
and C and a reduction of 40% compared with Group D with
a signiﬁcance level (P= 0.05). Oneway analysis of variance ser-
ies (ANOVA)were conducted to examine differences among the
four groups with respect to parametric variables. If there was a
signiﬁcant difference, Student’s t-test was used to detect inter-
group differences. Categorical variables were analyzed by v2
and Fisher test. A P< 0.05 was considered signiﬁcant.
3. Results
The four treatment groups were comparable with respect to
sex, age, BMI, menstrual cycle period, prior use of cigarettes,nt scores, anesthetic and surgical data.
B (n= 52) Group C (n= 52) Group D (n= 52)
0 31 ± 9 32 ± 11
22/30 21/31
24 ± 3 23 ± 3
.8) 11 (21.2) 17 (32.7)
10 (19.2) 4 (7.7)
8 (15.4) 6 (11.5)
0 6
32 35
1 0
2 2
1 1
19 160 ± 29 158 ± 30
43 169 ± 49 158 ± 35
4 30 ± 15 27 ± 15
48 131 ± 63 137 ± 68
46 115 ± 61 124 ± 66
1 17 ± 8 16 ± 10
1 19 ± 8 20 ± 11
8 38 ± 12 38 ± 17
ausea and vomiting, VAS = verbal analog scale.
Table 2 Incidence of nausea and vomiting (moderate > 40 mm on VAS) persisting for 15 min or more, and response to treatment.
Group A (n= 52) Group B (n= 52) Group C (n= 52) Group D (n= 52)
n (%) (95% CI)
Vomiting (PACU) 6 (11.5) (3–20)a 4 (7.7) (5–14)bc 13 (25) (13–37) 20 (38.5) (25–52)
Nausea (PACU) 4 (7.7) (4.5–14)bc 2 (3.8) (1–9)dc 13 (25) (13–36) 21 (40.4) (27–54)
Rescue treatment (PACU) 3 (5.8) (5–12)dc 2 (3.8) (1–9)dc 13 (25) (13–37) 19 (36.5) (23–49)
Failed treatment (PACU) 7 (13.5) (4–23)bc 5 (9.6) (2–17)dc 13 (25) (13–37) 23 (44.2) (22–49)
Failed treatment (24 h) 2 (3.8) (–0.14–9)bc 6 (11.5) (3–20)d 16 (30.8) (20–45) 11 (21.2) (10–32)
The values are numbers (n) or percentages (%) and conﬁdence intervals (CI) 95% of the percentages.
a P< 0.05 compared with Group D.
b P< 0.05 compared with Group C.
c P< 0.01 compared with Group D.
d P< 0.01 compared with Group C.
Table 3 Time proﬁles of intermediate and late recovery and verbal scores on scales similar to hospital discharge.
Group A (n= 51) Group B (n= 51) Group C (n= 51) Group D (n= 51)
Nausea VAS (0–100 mm) 8a 27b 46 77
Anxiety VAS (0–100 mm) 17 4 15 27
Sedation VAS (0–100 mm)
Vertigo VAS (0–100 mm) 33 33 17 31
Pain VAS (0–100 mm) 7 4 10 32
PACU stay time (min) 9 10 9 12
Ambulation time (min) 30 ± 6a 25 ± 5a 39 ± 4 54 ± 6
Tolerance to liquids (min) 193 ± 66ac 187 ± 76ac 278 ± 155 267 ± 146
Work return (days) 350 ± 178ad 351 ± 132ad 424 ± 176 478 ± 245
4 ± 1 4 ± 1 5 ± 1 4 ± 1
Values are mean ± SD, numbers (n).
VAS: visual analog scale.
a P< 0.01 compared with Group D.
b P< 0.05 compared with Group D.
c P< 0.01 compared with Group C.
d P< 0.05 compared with Group C.
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were no differences in preoperative assessment for patients
regarding verbal scales of nausea, anxiety, sedation, dizziness
and pain. The doses of fentanyl, propofol, rocuronium, neo-
stigmine and atropine were similar in all groups, like the time
of anesthesia and surgical time of eye opening, and command
guidance (Table 1).
During pre-hospital discharge, the number of patients expe-
riencing full prophylactic treatment response was signiﬁcantly
higher in dexamethasone Group (B) and dexamethasone
metoclopramide (A) when compared with placebo (D) and
metoclopramide alone (C). Complete response was similar
among patients who received dexamethasone alone (Group
B) and dexamethasone–metoclopramide combination
(Group A) and those who were given metoclopramidealone
(Group C) and placebo (Group D) (Table 2). Also Table 2
shows the incidences of PONV persisted for 15 min or more
and request for antiemetic therapy in each group.
In a post hoc analysis on the use of postoperative analgesia,
the dose of morphine was signiﬁcantly lower in Group A
[(dexamethasone–metoclopramide) 10.4 ± 3.2 mg] and Group
B [(dexamethasone) 10.3 ± 3.6 mg] with respect to Group D
[(placebo) 17.7 mg ± 5.6 mg] (P< 0.05). One patient in
Group A was hospitalized for intractable pain. Evaluationscarried out with verbal scales similar to hospital discharge re-
vealed no differences in anxiety, dizziness, sedation or pain.
However, nausea scores were signiﬁcantly higher in Group D
compared with Groups A and C (Table 3). Patients who
received dexamethasone–metoclopramide and dexamethasone
alone had a shorter stay in the PACU and met the hospital dis-
charge criteria signiﬁcantly faster than patients who received
metoclopramide or placebo. Similar results were obtained with
the time interval to achieve the real output of unassisted ambu-
lation and oral tolerance to liquids. These variables also did
not differ between dexamethasone–metoclopramide and dexa-
methasone alone groups and between metoclopramide and
placebo groups (Table 3).
The assessment that carried out at 24 h showed that the
proportion of patients with complete response in this period
was signiﬁcantly higher in the dexamethasone–metoclopra-
mide group compared with metoclopramide alone and placebo
groups and similarly in the dexamethasone alone compared
with the metoclopramide alone groups. The proportion of
treatment failures in the metoclopramide and placebo groups
were similar (Table 2).
There were no differences in the time of reinstatement work
(Table 3) and there was no evidence of surgical wound infec-
tion in any of the 208 participating patients.
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This study demonstrated that administration of dexametha-
sone as a single medication, is equally effective like the combi-
nation of dexamethasone–metoclopramide to prevent PONV
in outpatient maxillofacial procedures. This means that the
addition of metoclopramide does not confer any additional
beneﬁt in the prevention of secondary event. It also shows that
metoclopramide administered as single prophylactic antiemetic
agent is comparable to placebo.
This study found that dexamethasone administered before
induction of anesthesia was associated with a reduction in
the incidence of failed prophylactic antiemetic therapy in
35% (incidence of treatment failure of 44.2% vs. baseline
9.6% in the dexamethasone group) and 31% when metoclo-
pramide was added. This reduction is greater than 26% re-
ported in a multifactorial study which included multiple risk
factors for PONV and surgical procedures [7].
Our study also found an incidence of 44.2% PONV in the
placebo group, which was lower than the incidence that dem-
onstrated by Apfel (59%) among those patients not receiving
prophylactic antiemetic therapy and who received volatile
anesthetic, nitrous oxide and fentanyl [7]. It should be noted
that in that study, the ENT procedures had the highest inci-
dence of PONV (14.3%) [11–13]. That is why our study popu-
lation represents a clinically relevant baseline risk of PONV as
the maxillofacial surgeries is not considered one of the high
risk surgeries for nausea and vomiting. Surprisingly, our inci-
dence of nausea in the PACU was similar to that of emesis, un-
like what usually reported [12,14].
Dexamethasone has proved more effective as a prophylactic
antiemetic when administered during anesthesia induction
[8,15,16]. There are several reasons why this time of implemen-
tation seems to be especially effective for reducing emetic symp-
toms; is associated with pre-incisional reduced levels of 5-
hydroxytryptophan in neural tissue by depleting its tryptophan
precursor (16), the anti-inﬂammatory properties of corticoste-
roids before the surgical incision can prevent the release of sero-
tonin in the gastrointestinal tract [17], and it is possible that early
administration of dexamethasone may potentiate the effects of
other antiemetics by sensitizing pharmacological receptors [18].
There is indirect evidence that metoclopramide may be
more effective as a prophylactic antiemetic when administered
at the end of surgery [19]. Ferrari and Donlon found that
0.15 mg/kg of metoclopramide upon arrival at the PACU
was an effective prophylactic antiemetic in children born to
adenoidectomy [20]. In contrast, Furst and Rodarte failed to
demonstrate antiemetic effect when 0.5 mg/kg of metoclopra-
mide was administered immediately after induction of anesthe-
sia [21]. The behavior of metoclopramide as a prophylactic
antiemetic in this study is consistent with results of previous
study: a dose of 10 mg IV antiemetic effects has no clinical rel-
evant [10]. It is likely that the dose used in this study (which is
routinely used in clinical practice) is big [22]. Its effect on 5-
HT3 receptors appear to be dose dependent and the lowest
dose to block these receptors is suspected [23]. Therefore there
is a require for further evaluation to determine the optimal
dose of metoclopramide in combination with dexamethasone
for the prevention of PONV without any improper blocking
dopamine receptors, the situation which is associated with
the presentation of the undesirable extrapyramidal effects.This study evaluated the treatment outcomes in two differ-
ent time periods. The short-term efﬁcacy is primarily an eco-
nomic impact in the ambulatory area [12]. The long-term
positive results are the best indicators of the antiemetic activity
and patient’s welfare [23].
The present study conﬁrms the early and late antiemetic
efﬁcacy of dexamethasone when compared to placebo that re-
ported in a recent systematic quantitative review [8]. However,
so far no results have been reported about the efﬁcacy of dexa-
methasone–metoclopramide combination in the prophylaxis of
PONV. By contrast, the use of this addition is purely anec-
dotal, and has in fact been adopted in antiemetic prophylaxis
protocols in some anesthesiology departments.
5. Conclusion
In conclusion, the combination of dexamethasone with meto-
clopramide was not signiﬁcantly more effective than single
administration of dexamethasone in the prophylaxis of PONV
in patients undergoing maxillofacial surgery. Therefore other
antiemetic agents such as haloperidol and antiserotoninergic,
added to dexamethasone may be considered for increase anti-
emetic prophylactic effectiveness [12,24]. Metoclopramide at
doses of 10 mg IV has no prophylactic antiemetic effects, the
fact that this is the only medication approved by the
prophylactic antiemetic Compulsory Health Plan must be
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